News
Long-term Efficacy, Safety, and Tolerability of Normal Human IgG with Facilitated Absorption in Patients with Humoral Immunodeficiency
The treatment of patients with humoral immunodeficiency is long-term and therefore needs to be not only effective but also safe and well-tolerated. Below, we present the outcomes from an Italian real-world clinical practice study evaluating the efficacy, safety, and tolerability of human immunoglobulin for facilitated subcutaneous administration and patient satisfaction with this therapy.
fSCIG in Elderly Patients with PID or SID in Real Clinical Practice
The work of a team of German and Dutch authors presents data on the real clinical use of 10%…
Current NCCN Recommendations for Classification and Risk Symptoms in SLL/CLL
The new recommendations from the National Comprehensive Cancer Network (NCCN) regarding chronic…
Electronic Cigarettes as an Alternative Option for Quitting Smoking?
Diseases caused by smoking tobacco products are a significant cause of global morbidity and…
Diabetes mellitus and heart failure − interconnected units with complex pathogenesis
Diabetes mellitus (DM) represents a significant risk factor for the development of heart failure.…
Teriflunomide "under the microscope" or what it's like to live with MS in the North
The Teri-LIFE study examined teriflunomide very comprehensively. How does it manage to affect the…
Cardiovascular Interventions with Continued Therapy with Dabigatran − Insights from the GLORIA-AF Study
An analysis using data from an international registry of patients with newly diagnosed atrial…
Smouldering Multiple Sclerosis: How Can MRI Help in Its Identification?
With the changing understanding of the etiopathogenesis of multiple sclerosis, several new…
Teriflunomide vs. Dimethyl Fumarate: Does Their Classification into Different Treatment Lines Have Merit?
Teriflunomide is one of the first-choice medications in the treatment of multiple sclerosis (MS)…
Prevalence of Heart Failure and Its Subtypes in the Population of Developed Countries
In developed countries, heart failure occurs in approximately 2% of the population, with an annual…